 Connection
Lia Gore to Myeloid-Lymphoid Leukemia Protein
This is a "connection" page, showing publications Lia Gore has written about Myeloid-Lymphoid Leukemia Protein.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.413 |
|
|
|
-
Guest EM, Kairalla JA, Hilden JM, Dreyer ZE, Carroll AJ, Heerema NA, Wang CY, Devidas M, Gore L, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Borowitz M, Loh ML, Hunger SP, Brown PA. Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial. Haematologica. 2022 05 01; 107(5):1205-1208.
Score: 0.192
-
Brown PA, Kairalla JA, Hilden JM, Dreyer ZE, Carroll AJ, Heerema NA, Wang C, Devidas M, Gore L, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Borowitz MJ, Small D, Loh ML, Hunger SP. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. Leukemia. 2021 05; 35(5):1279-1290.
Score: 0.177
-
Gore L, Ess J, Bitter MA, McGavran L, Meltesen L, Wei Q, Hunger SP. Protean clinical manifestations in children with leukemias containing MLL-AF10 fusion. Leukemia. 2000 Dec; 14(12):2070-5.
Score: 0.044
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|